Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures

NCT ID: NCT05076110

Last Updated: 2025-06-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

188 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-07

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to evaluate the effectiveness of post-operative pain control without using narcotic pain medications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Arthroscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care Group

Subjects will receive standard of care pain medication Oxycodone for pain control following hip arthroscopy procedure

Group Type ACTIVE_COMPARATOR

Oxycodone

Intervention Type DRUG

5 mg tablets every 4 hours postoperatively as needed for pain control

Non-Opiate Pain Control Group

Subjects will receive a non-opiate pain control regime using Ibuprofen, Gabapentin, Acetaminophen, Methocarbamol for pain control following hip arthroscopy procedure.

Group Type EXPERIMENTAL

Ibuprofen

Intervention Type DRUG

800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day

Gabapentin

Intervention Type DRUG

300 mg three times a day for 5 days then wean off by day 10 postoperatively

Acetaminophen

Intervention Type DRUG

1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day

Methocarbamol

Intervention Type DRUG

500 mg three times a week for 2 weeks postoperatively

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxycodone

5 mg tablets every 4 hours postoperatively as needed for pain control

Intervention Type DRUG

Ibuprofen

800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day

Intervention Type DRUG

Gabapentin

300 mg three times a day for 5 days then wean off by day 10 postoperatively

Intervention Type DRUG

Acetaminophen

1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day

Intervention Type DRUG

Methocarbamol

500 mg three times a week for 2 weeks postoperatively

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Robaxin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Scheduled for a primary Hip Arthroscopy at Mayo Clinic (Rochester, MN)

Exclusion Criteria

* medical history of known allergies or intolerance to allergies or intolerance to Motrin, Gabapentin, Tylenol, dexamethasone, tramadol, or Robaxin.
* Substantial alcohol or drug abuse.
* History of narcotics within 6 months of surgery.
* Pregnancy.
* Renal impairment.
* Peptic ulcer disease.
* GI bleeding.
Minimum Eligible Age

16 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kelechi R. Okoroha

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kelechi Okoroha, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo clinic

Rochester, Minnesota, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

kelechi R okoroha

Role: primary

832-423-9895

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21-003441

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Opioid-Sparing Joint Replacement
NCT07348627 NOT_YET_RECRUITING PHASE3
NSAID vs. Narcotics
NCT02915055 COMPLETED
Nonopioid Analgesia After Labral Surgery
NCT03825809 RECRUITING PHASE2/PHASE3